GlaxoSmithKline Pays $10.6 Billion for Cancer Drug Company with No Approved Products

GSK agreed to buy Nuvalent, a cancer biotech firm with no approved drugs yet, for $10.6 billion in cash. At $124 per share, the all-cash deal—with no clawbacks if the drugs flop—shows big pharmaceutical companies still see value in experimental treatments despite biotech sector troubles.